Does preoperative semaglutide reduce 90-day adverse outcomes in patients with type II diabetes undergoing total shoulder arthroplasty?
Preoperative semaglutide use is associated with reduced 90-day adverse outcomes in patients with type II diabetes undergoing total shoulder arthroplasty.
The current study encouragingly found reductions in 90-day adverse outcomes following TSA for patients with T2DM using semaglutide preoperatively. Further prospective analysis is warranted as the observed findings suggest clinical benefit of semaglutide integration into preoperative optimization pathways by the studied patient population.
Seddio et al. (Thu,) studied this question.